LSD1 Facilitates Pro-Inflammatory Polarization of Macrophages by Repressing Catalase
Overview
Biophysics
Cell Biology
Molecular Biology
Authors
Affiliations
The increased level of hydrogen peroxide accompanies some modes of macrophage specification and is linked to ROS-based antimicrobial activity of these phagocytes. In this study, we show that activation of toll-like receptors with bacterial components such as LPS is accompanied by the decline in transcription of hydrogen peroxide decomposing enzyme-catalase, suppression of which facilitates the polarization of human macrophages towards the pro-inflammatory phenotype. The chromatin remodeling at the promoter involves LSD1 and HDAC1, but activity of the first enzyme defines abundance of the two proteins on chromatin, histone acetylation status and the transcription. LSD1 inhibition prior to macrophage activation with LPS prevents repression by enhancing the LSD1 and interfering with the HDAC1 recruitment to the gene promoter. The maintenance of catalase level with LSD1 inhibitors during M1 polarization considerably limits LPS-triggered expression of some pro-inflammatory cytokines and markers such as , , , , , and , but the effect of LSD1 inhibitors is lost upon catalase deficiency. Summarizing, activity of LSD1 allows for the repression in LPS stimulated macrophages, which negatively controls expression of some key pro-inflammatory markers. LSD1 inhibitors can be considered as possible immunosuppressive drugs capable of limiting macrophage M1 specialization.
Liu K, Li Y, Shen M, Xu W, Wu S, Yang X Biomolecules. 2025; 15(1).
PMID: 39858465 PMC: 11764280. DOI: 10.3390/biom15010071.
Bahl A, Pandey S, Rakshit R, Kant S, Tripathi D Infect Immun. 2024; 93(1):e0047224.
PMID: 39655962 PMC: 11784091. DOI: 10.1128/iai.00472-24.
Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways.
Zhang Y, Guo N, Zhu H, Liu M, Hao J, Wang S Theranostics. 2024; 14(18):7054-7071.
PMID: 39629133 PMC: 11610140. DOI: 10.7150/thno.102037.
Mamun M, Zhang Y, Zhao J, Shen D, Guo T, Zheng Y J Biomed Sci. 2023; 30(1):60.
PMID: 37525190 PMC: 10391765. DOI: 10.1186/s12929-023-00952-0.
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential.
Bao L, Zhu P, Mou Y, Song Y, Qin Y Front Immunol. 2023; 14:1214675.
PMID: 37483603 PMC: 10360200. DOI: 10.3389/fimmu.2023.1214675.